136 related articles for article (PubMed ID: 17329297)
1. Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI).
Dunbar GC; Inglis F; Kuchibhatla R; Sharma T; Tomlinson M; Wamsley J
J Psychopharmacol; 2007 Mar; 21(2):171-8. PubMed ID: 17329297
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers.
Dunbar G; Demazières A; Monreal A; Cisterni C; Metzger D; Kuchibhatla R; Luthringer R
J Clin Pharmacol; 2006 Jul; 46(7):715-26. PubMed ID: 16809797
[TBL] [Abstract][Full Text] [Related]
3. A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment.
Dunbar GC; Kuchibhatla RV; Lee G;
J Psychopharmacol; 2011 Aug; 25(8):1020-9. PubMed ID: 20542923
[TBL] [Abstract][Full Text] [Related]
4. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
[TBL] [Abstract][Full Text] [Related]
5. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease.
Parkinson Study Group
Neurology; 2006 Feb; 66(3):408-10. PubMed ID: 16476941
[TBL] [Abstract][Full Text] [Related]
6. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study.
Wilens TE; Verlinden MH; Adler LA; Wozniak PJ; West SA
Biol Psychiatry; 2006 Jun; 59(11):1065-70. PubMed ID: 16499880
[TBL] [Abstract][Full Text] [Related]
7. A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder.
Bain EE; Apostol G; Sangal RB; Robieson WZ; McNeill DL; Abi-Saab WM; Saltarelli MD
J Clin Psychiatry; 2012 Jun; 73(6):783-9. PubMed ID: 22795204
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
Barbier AJ; Hilhorst M; Van Vliet A; Snyder P; Palfreyman MG; Gawryl M; Dgetluck N; Massaro M; Tiessen R; Timmerman W; Hilt DC
Clin Ther; 2015 Feb; 37(2):311-24. PubMed ID: 25438724
[TBL] [Abstract][Full Text] [Related]
9. Cognitive enhancement in man with ispronicline, a nicotinic partial agonist.
Dunbar GC; Kuchibhatla R
J Mol Neurosci; 2006; 30(1-2):169-72. PubMed ID: 17192668
[TBL] [Abstract][Full Text] [Related]
10. Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers.
Othman AA; Lenz RA; Zhang J; Li J; Awni WM; Dutta S
J Clin Pharmacol; 2011 Apr; 51(4):512-26. PubMed ID: 20495134
[TBL] [Abstract][Full Text] [Related]
11. Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial.
Barch DM; Marder SR; Harms MP; Jarskog LF; Buchanan RW; Cronenwett W; Chen LS; Weiss M; Maguire RP; Pezous N; Feuerbach D; Lopez-Lopez C; Johns DR; Behrje RB; Gomez-Mancilla B
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():66-75. PubMed ID: 27371157
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a nicotine (4 mg)-containing lozenge on the cognitive impairment of nicotine withdrawal.
Atzori G; Lemmonds CA; Kotler ML; Durcan MJ; Boyle J
J Clin Psychopharmacol; 2008 Dec; 28(6):667-74. PubMed ID: 19011436
[TBL] [Abstract][Full Text] [Related]
13. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers.
Faessel HM; Smith BJ; Gibbs MA; Gobey JS; Clark DJ; Burstein AH
J Clin Pharmacol; 2006 Sep; 46(9):991-8. PubMed ID: 16920893
[TBL] [Abstract][Full Text] [Related]
14. Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.
Algorta J; Pena MA; Alvarez A; Maraschiello C; Maruhn D; Windisch M; Mucke HA
Int J Clin Pharmacol Ther; 2009 Jul; 47(7):483-90. PubMed ID: 19640356
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
16. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers.
Otmani S; Demazières A; Staner C; Jacob N; Nir T; Zisapel N; Staner L
Hum Psychopharmacol; 2008 Dec; 23(8):693-705. PubMed ID: 18763235
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
[TBL] [Abstract][Full Text] [Related]
18. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
Stonnington CM; Snyder PJ; Hentz JG; Reiman EM; Caselli RJ
J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495
[TBL] [Abstract][Full Text] [Related]
19. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers.
Dunbar G; Boeijinga PH; Demazières A; Cisterni C; Kuchibhatla R; Wesnes K; Luthringer R
Psychopharmacology (Berl); 2007 May; 191(4):919-29. PubMed ID: 17225162
[TBL] [Abstract][Full Text] [Related]
20. Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance.
Buccafusco JJ; Letchworth SR; Bencherif M; Lippiello PM
Trends Pharmacol Sci; 2005 Jul; 26(7):352-60. PubMed ID: 15946748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
